¾«¶«Ó°Òµ

Robin Feldman - Bibliography

Publications

  • Books

  • DRUGS, MONEY, AND SECRET HANDSHAKES: THE UNSTOPPABLE GROWTH OF PRESCRIPTION DRUG PRICES (Cambridge ¾«¶«Ó°Òµ Press 2019).
  • DRUG WARS: HOW BIG PHARMA RAISES PRICES AND KEEPS GENERICS OFF THE MARKET (Cambridge Univ. Press 2017) (with Evan Frondorf).
  • RETHINKING PATENT LAW (Harvard Univ. Press 2012).
  • THE ROLE OF SCIENCE IN LAW (Oxford Univ. Press 2009).

  • Chapters in Books

  • Intellectual Property: Naked Price & Pharmaceutical Trade Secret Overreach, in 5 The Judges’ Book 93 (Scott Dodson ed., UC Hastings 2021).
  • Competition at the Dawn of Artificial Intelligence, in Competition Law for the Digital Economy 71 (Björn Lundqvist & Michal S. Gal eds., Edward Elgar 2019) (with Nick Thieme) (peer reviewed).
  • Learning from Past Mistakes – The US Patent System and International Trade Agreements, in Megaregionalism 2.0: Trade and Innovation within Global Networks 145 (Dieter Ernst & Michael G. Plummer eds., World Scientific Studies in International Economics 2018).
  • Coming to the ¾«¶«Ó°Òµ, in Imagining New Legalities: Privacy and Its Possibilities in the 21st Century 84 (Austin Sarat et al.eds., Amherst Series in Law, Jurisprudence & Social Thought, Stanford Univ. Press 2012).
  • Patent Misuse: From Inception to Modern Case Law, in 2 Intellectual Property and Information Wealth: Issues and Practices in the Digital Age 137 (Peter K. Yu ed., Praeger Publishers 2007).

  • Book Reviews

  • Book Review, 34 Governance 263 (2021) (reviewing GERALD POSNER, PHARMA: GREED, LIES, AND THE POISONING OF AMERICA).
  • For the Love of Licensing, 18 Va. J.L. & Tech. 178 (2013) (reviewing CYNTHIA CANNADY, TECHNOLOGY LICENSING AND DEVELOPMENT AGREEMENTS).

  • Journal Articles

  • Pharmaceutical Mergers: Do We Have The Right Cure?. 27 Colum. Sci. & Tech. L. Rev. 69 (2026) (with Gideon Schor, Yaniv Konchitchki & Tanziuzzaman Sakib).
  • AI & Antitrust: The Algorithm Made Me Do It, 34 Competition: J. Anti. & Unfair Comp. L. Sec. Cal. L. Assoc. 1 (2024). ,
  • Dance of the Biologics, 39 Berkeley Tech. L.J. 841 (2024). ,
  • Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act, 21 PLoS Med. (4) (2024).
  • CalRx Biosimilar Insulin: California’s Initiative to Enter the Insulin Market, 183 JAMA Internal Med. 1043 (2023).
  • Leading With the Trailing Edge: Facilitating Patient Choice for Insulin Products, 10 J. L. & Biosci. 1 (2023).
  • Insulin: California’s Initiative to Enter the Insulin Market, JAMA Internal Med. (2023).
  • CalRx Biosimilar Insulin: California’s Initiative to Enter the Insulin Market, 183 JAMA Internal Med. 1043 (2023).
  • Patents as Property for the Takings, 12 N.Y.U. J. Intell. Prop. & Ent. L. 198 (2023). ,
  • Advertising Medicine: Selling the Cure, 26 Stan. Tech. L. Rev. 1 (2023). ,
  • Trade Secrets in Biologic Medicine: The Boundary with Patents, 24 Colum. Sci. & Tech. L. Rev. 1 (2022). ,
  • The Price Tag of ‘Pay-for-Delay’, 23 Colum. Sci. & Tech. L. Rev. 1 (2022). ,
  • Designing Disruption in Pharmaceuticals, 28 B.U. J. Sci. & Tech. L. 1 (2022). ,
  • Captive Generics: The Wolf in Sheep’s Clothing, 59 Harv. J. on Legis. 383 (2022). ,
  • A Patient Price Guide for Prescription Medication, 175 Annals Internal Med. 885 (2022) (with Natalie Feldman & Enrique Seoane-Vazquez).
  • Understanding “Evergreening”: Making Minor Modifications Of Existing Medications To Extend Protections, 41 Health Aff. 801 (2022).
  • Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation, 47 J. Health Pol. Pol’y & L. 583 (2022) (with Brent D. Fulton; Jamie R. Godwin & Richard M. Scheffler).
  • Combination Therapy Patents: A New Front in Evergreening, 39 Nature Biotech. 1504 (2021) (with Garth W. Strohbehn; Alec J. Kacew; Daniel A. Goldstein & Mark J. Ratain).
  • The Devil in the Tiers, 8 J. L. & Biosci. 1 (2021).
  • AI Governance in the Financial Industry, 27 Stan. J.L. Bus. & Fin. 94 (2021) (with Kara Stein).
  • Negative Innovation: When Patents Are Bad for Patients, 39 Nature Biotech. 914 (2021) (with David A. Hyman et al.).
  • The Arc of History in Patent Subject Matter, 11 Hastings Sci. & Tech. L.J. 1 (2020).
  • Regulatory Property: The New IP, 40 Colum. J.L. & Arts 53 (2016). ,
  • Startups and Unmet Legal Needs, 2016 Utah L. Rev. 575 (2016) (with Alice Armitage; Evan Frondorf; and Christopher Williams). ,
  • The CRISPR Revolution: What Editing Human DNA Reveals About the Patent System’s DNA, 64 UCLA L. Rev. Disc. 392 (2016). ,
  • Patent Licensing, Technology Transfer and Innovation, 106 Am. Econ. Rev. 188 (2016) (with Mark A. Lemley).
  • Do Patent Licensing Demands Mean Innovation?, 101 Iowa L. Rev. 137 (2015) (with Mark A. Lemley). ,
  • Federalism, First Amendment & Patents: The Fraud Fallacy, 17 Colum. Sci. & Tech. L. Rev. 30 (2015). ,
  • Human Cells and Cultural Property, 21 Int’l J. Cultural Prop. 243 (2014).
  • Patent Trolling: Why Bio & Pharmaceuticals Are at Risk, 17 Stan. Tech. L. Rev. 773 (2014) (with W. Nicholson Price II).
  • Coming of Age for the Federal Circuit, 17 Green Bag 2d 27 (2014).
  • Gene Patenting After the U.S. Supreme Court Decision—Does Myriad Matter?, 26 Stan. L. & Pol’y Rev. 16 (2014).
  • Transparency, 19 Va. J.L. & Tech. 271 (2014). ,
  • Patent Demands & Startup Companies: The View from the Venture Capital ¾«¶«Ó°Òµ, 16 Yale J.L. & Tech. 236 (2014). ,
  • Ending Patent Exceptionalism & Structuring the Rule of Reason: The Supreme Court Opens the Door for Both, 15 Minn. J. L. Sci. & Tech. 61 (2014).
  • The Pace of Change: Non-Practicing Entities and the Shifting Legal Landscape, 18 Chapman L. Rev. 635 (2014).
  • A Conversation on Judicial Decision-Making, 5 Hastings Sci. & Tech. L.J. 1 (2013). ,
  • Copyright at the Bedside: Should We Stop the Spread?, 16 Stan. Tech. L. Rev. 623 (2013) (with John Newman). ,
  • The AIA 500 Expanded: Effects of Patent Monetization Entities, 17 UCLA J.L. & Tech. 1 (2013) (with Tom Ewing & Sara Jeruss).
  • Intellectual Property Wrongs, 18 Stan. J.L. Bus. & Fin. 250 (2013). ,
  • The America Invents Act 500: Effects of Patent Monetization Entities on US Litigation, 11 Duke L. & Tech. Rev. 357 (2012) (with Sara Jeruss & Joshua H. Walker).
  • The Giants Among Us, 2012 Stan. Tech. L. Rev. 1 (2012) (with Tom Ewing). ,
  • Understanding and Incentivizing Biosimilars, 64 Hastings L.J. 57 (2012) (with Jason Kantor). ,
  • Whose Body Is It Anyway? Human Cells and the Strange Effects of Property and Intellectual Property Law, 63 Stan. L. Rev. 1377 (2011). ,
  • Copyright and Open Access at the Bedside, 365 New Eng. J. Med. 2449 (2011) (with John Newman).
  • The Intellectual Property Landscape for iPS Cells, 3 Stan. J.L. Sci. & Pol’y 16 (2010) (with Deborah Furth). ,
  • The Role of the Subconscious in Intellectual Property Law, 2 Hastings Sci. & Tech. L.J. 1 (2010). ,
  • Plain Language Patents, 17 Tex. Intell. Prop. L.J. 289 (2009). ,
  • Historic Perspectives on Law & Science, 2009 Stan. Tech. L. Rev. 1 (2009). ,
  • Law’s Misguided Love Affair with Science, 10 Minn. J. L. Sci. & Tech. 95 (2009). ,
  • Patent and Antitrust: Differing Shades of Meaning, 13 Va. J.L. & Tech. 5 (2008). ,
  • Open Source.Open Access.Open Transfer: Market Approaches to Research Bottlenecks, 7 Nw. J. Tech. & Intell. Prop. 14 (2008) (with Kris Nelson). ,
  • The Inventor’s Contribution, 2005 UCLA J.L. & Tech. 6 (2005). ,
  • Rethinking Rights in Biospace, 79 S. Cal. L. Rev. 1 (2005). ,
  • The Open Source Biotechnology Movement: Is It Patent Misuse?, 6 Minn. J. L. Sci. & Tech. 117 (2004). ,
  • Considerations on the Emerging Implementation of Biometric Technology, 25 Hastings Comm. & Ent. L.J. 653 (2003). ,
  • The Insufficiency of Antitrust Analysis for Patent Misuse, 55 Hastings L.J. 399 (2003). ,
  • Consumption Taxes and the Theory of General and Individual Taxation, 21 Va. Tax Rev. 293 (2002). ,
  • Defensive Leveraging in Antitrust, 87 Geo. L.J. 2079 (1999). ,

  • Newspaper & Magazine Articles

  • Cutting-Edge Insulin is Good. But it’s the ‘Trailing Edge’ of Older Versions That Can Keep it Affordable, Wash. Post, May 15, 2024.
  • The Problem with Direct-to-Consumer Pharmaceutical Advertising, Wash. Post, Mar. 2, 2023.
  • We Need a Labeling System for Pharmaceutical Prices, Wash. Post, Jun. 10, 2022 (with Natalie Feldman & Enrique Seoane-Vazquez).
  • What Is the Price of a Prescription Drug?, Promarket, Feb. 4, 2021.
  • Drug Companies Keep Merging. Why That’s Bad for Consumers and Innovation, Wash. Post, Apr. 6, 2021.
  • Our Patent System is Broken. And it Could Be Stifling Innovation, Wash. Post, Aug. 8, 2021 (Op-Ed).
  • The Perils of Value-Based Pricing for Prescription Drugs, Wash. Post, Apr. 11, 2019.
  • Why the Cancer “Moonshot” Has Been So Disappointing, Wash. Post, Sep. 14, 2019.
  • ‘One-and-Done’ for New Drugs Could Cut Patent Thickets and Boost Generic Competition, STAT, Feb. 11, 2019.
  • Why Prescription Drug Prices Have Skyrocketed, Wash. Post, Nov. 26, 2018.
  • Pharma Companies Fight Behind-the-Scenes Wars Over Generic Drugs, STAT, Jun. 16, 2017.
  • How Big Pharma Is Hindering the Treatment of the Opioid Addiction Epidemic, The Conversation, Aug. 7, 2017.
  • Next Patent Troll Victims: Pharma & Bio?, The Hill, Mar. 28, 2014.
  • Slowing the Patent Trolls, N.Y. Times, Mar. 28, 2014.
  • You Patented It, You Own It? Not So Fast, Bos.Globe, Jan. 20, 2013.
  • FTC Must Move Quickly Against Patent Trolls, S.F. Chron., 21-Jul 2013.
  • Shedding Light on ‘Prometheus’, 10 The Recorder, Mar. 9, 2012.

  • Miscellaneous

  • Incentivizing Failure, UC Hastings Research Paper (2021).
  • Pharmaceutical Pipeline Divestitures Study: Preliminary Results, UC Hastings Research Paper (2021).
  • States’ Rights: A Patent Law Analysis of NASHP Rate-Setting Model Act, National Association of State Health Policy White Paper (Mar-18 2018) (with Betty Chang Rowe, Rabiah Oral. Amy Y. Gu, & Katherine Gudiksen).
  • Comment on the Food and Drug Administration (FDA) Notice: Administering the Hatch-Waxman Amendments, Ensuring a Balance Between Innovation and Access, (Sept. 18, 2017).
  • Learning from Past Mistakes – The US Patent System and International Trade Agreements, Working Paper, East-West Center Workshop on Mega-Regionalism – New Challenges for Trade and Innovation (2016).